Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations
Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.
Source: onclive.com
Michael Deininger News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Deininger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Deininger Today - Breaking & Trending Today
A Look Into Selecting TKIs for CML Treatment
Given the wealth of available options, the selection of tyrosine kinase inhibitors for patients with chronic myeloid leukemia is faced with a plethora of nuanced decisions.
Source: onclive.com
TKI Selection in CML Demands Nuanced Approaches
Choosing the most effective TKIs for individual patients with chronic myeloid leukemia requires decision making based on efficacy data, agent safety profiles, and patient characteristics, according to Michael Deininger, MD.
Source: onclive.com
Expansion Plans for Versiti Blood Research Institute Win Key Support from Wisconsin's Joint Committee on Finance
MILWAUKEE, June 7, 2023 /PRNewswire/ -- Versiti Wisconsin expresses its sincere gratitude to the members of the Joint Finance Committee for approving a $10 million grant to expand Versiti's Blood
Source: wsiltv.com